4.4 Article

Autoimmunity and the risk of myeloproliferative neoplasms

期刊

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 95, 期 7, 页码 1216-1220

出版社

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2009.020412

关键词

myeloproliferative neoplasms; autoimmune diseases; polycythemia vera. essential thrombocythema; primary myelofibrosis; Crohn's disease; immune thrombocytopenic purpura; giant cell arteritis; polymyalgia rheumatica; aplastic anemia

资金

  1. NIH
  2. National Cancer Institute
  3. Swedish Cancer Society
  4. Stockholm County Council
  5. Karolinska Institutet Foundations
  6. Shire Pharmaceuticals

向作者/读者索取更多资源

The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of myeloproliferative neoplasm. We found a prior history of any autoimmune disease to be associated with a significantly increased risk of myeloproliferative neoplasms (odds ratio (OR)=1.2; 95% confidence interval (CI) 1.0-1.3; P=0.021). Specifically, we found an increased risk of MPNs associated with a prior immune thrombocytopenic purpura (2.9; 1.7-7.2), Crohn's disease (1.8; 1.1-3.0), polymyalgia rheumatica (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter's syndrome (15.9; 1.8-142) and aplastic anemia (7.8; 3.7-16.7). The risk of myeloproliferative neoplasms associated with prior autoimmune diseases is modest but statistically significant. Future studies are needed to unravel the effects of these autoimmune diseases themselves, their treatment, or common genetic susceptibility.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据